Experience

Davis Polk advised the joint book-running managers and the co-managers in connection with the $349.3 million public offering of common stock by Portola Pharmaceuticals, Inc. The…

 Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $750 million aggregate principal amount of its 3.000% senior…

Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceuticals plc, of $500 million aggregate…

Davis Polk advised the underwriter in connection with the $39.3 million SEC-registered offering of 2,500,000 ordinary shares of Oxford Immunotec Global PLC. The ordinary shares are…

Davis Polk advised the joint book-running managers and representatives of the underwriters on the $201 million public offering by BeiGene, Ltd. of American Depositary Shares. The ADSs…

Davis Polk advised the sole book-running manager on an SEC-registered offering by Celgene Corporation of $500 million aggregate principal amount of 2.250% senior notes due 2021. …

Davis Polk advised the representative of the underwriters in connection with the $402.5 million public offering of 5,296,053 shares of common stock of Spark Therapeutics, Inc. The…

Davis Polk advised Accuray Incorporated in connection with a private exchange of approximately $47 million aggregate principal amount of its outstanding 3.50% convertible senior notes due…

Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of Sienna Biopharmaceuticals, Inc., including shares sold pursuant to…

Davis Polk advised Biotoscana Investments S.A. and the selling shareholders in connection with an initial public offering of 44,550,000 common shares, including common shares in the form of…